Table 3. Comparison of the clinical characteristics of HRD to NAD patients.
| HRD (n = 143) | NAD (n = 213) | P value | |
|---|---|---|---|
| Age at Diagnosis, years | 0.0001 | ||
| Mean (SD) | 58.4 (10.6) | 63.1 (11.5) | |
| Histology | 0.0004 | ||
| High grade serous | 118 (45%) | 146 (55%) | |
| High grade endometrioid | 10 (37%) | 17 (63%) | |
| Low grade endometrioid | 2 (9%) | 21 (91%) | |
| Clear Cell | 5 (28%) | 13 (72%) | |
| Low grade Serous | 2 (15%) | 11 (85%) | |
| Mucinous | 0 (0%) | 5 (100%) | |
| Other/Unknown | 6 (100%) | 0 (0%) | |
| Grade | <0.0001 | ||
| High | 135 (44%) | 174 (66%) | |
| Low | 5 (11%) | 39 (89%) | |
| Unknown | 3 (100%) | 0 (0%) | |
| First Degree Family History of Breast or Ovarian Cancer | 0.0020 | ||
| No | 104 (36%) | 183 (64%) | |
| Yes | 39 (57%) | 30 (43%) | |
| First Degree Family History of Ovarian Cancer | 0.0344 | ||
| No | 132 (39%) | 207 (61%) | |
| Yes | 11 (65%) | 6 (35%) |
Only patients with known HRD status (germline mutation, somatic mutation and somatic methylation) available were included; VUS carriers are included in NAD patient group; stage, debulking, presence of ascites, peritoneal cytology, smoking history, enrollment year, alcohol use were not significantly different between HRD and NAD patients.